Scenesse improves life quality in EPP adults: Real-world study

Scenesse improves life quality in EPP adults: Real-world study

Short- and long-term treatment with Scenesse (afamelanotide) improves life quality in adults with erythropoietic protoporphyria (EPP), according to the largest real-world study of its kind. The therapy’s safety profile among those over 70 was consistent with that of the overall patient population, with nausea, cold-like symptoms, headache, and fatigue…

Boy’s congenital erythropoietic porphyria diagnosis takes years

A boy’s long medical odyssey, which eventually led to a diagnosis of congenital erythropoietic porphyria (CEP) but left the child with long-term disabilities, demonstrates the need for timely recognition of this rare form of porphyria, per a report from India. “This case report illustrates the complex and challenging journey…

Fighting for change on Capitol Hill

Last week was a rallying cry for rare disease patients, their families, and other advocates to make their voices heard. I spent time on Capitol Hill in Washington, D.C., standing alongside fellow advocates for a week of activity centered on Friday’s Rare Disease Day. Representing the United Porphyrias Association…

Thank you for writing, but we have a no-return policy

To whom it may concern, I, Kalyn Shelton, wish to return my body as well as my mind because of chronic fatigue, nausea, pain, anxiety, depression, and more. I received this item a little over 30 years ago and began experiencing severe issues in July 2020. Please be advised that…